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Abstract
Hepatitis C virus was discovered nearly 30 years ago, and for the first two decades, treat-
ment was limited to agents with low response rates and substantial side effects. Since 
the introduction of direct-acting antivirals, there have been rapid advances made toward 
even higher sustained virologic responses (SVRs) and fewer side effects. This chapter 
provides a review of the newer agents for treatment of hepatitis C and highlights spe-
cial populations, including those coinfected with HIV or hepatitis B, previously treated 
patients, and post-liver transplant patients.
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1. Introduction
Hepatitis C virus (HCV) infects approximately 185 million individuals worldwide and is the 
leading indication for liver transplant in the United States (US) [1]. In 2014, the centers for disease 
control and prevention (CDC) reported an estimated 30,500 new cases of HCV in the US, while 
the estimated number of chronic cases was approximately 2.7–3.9 million. HCV was first discov-
ered in 1989, and there have been numerous advances in medical therapies available for the treat-
ment and cure of HCV infection. Cure is defined as a sustained virologic response (SVR), which 
means undetectable levels of plasma HCV RNA for 12 or 24 weeks after completion of therapy.
The first agents available for treatment of HCV were the alfa interferons, which are immu-
nomodulatory agents administered subcutaneously. The initial treatment regimen with 
interferon monotherapy resulted in SVR rates of only approximately 15% [2]. Ribavirin was 
subsequently added, which improved SVR rates to 33 and 41% for 24- and 48-week treatment 
regimens, respectively [3]. With the introduction of pegylated interferon (peg-IFN), SVR rates 
© 2017 The Author(s). Licensee InTech. Distributed under the terms of the Creative Commons Attribut on-
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increased up to an estimated 50% [4]. Despite significant side effects, a suboptimal SVR rate, 
the need for prolonged therapy, and parenteral injections, Peg-IFN and ribavirin were the 
standard of care for over a decade.
The most recent development in treatment of HCV was the introduction of direct-acting anti-
virals (DAAs), which target various stages in the HCV life cycle. In 2014, an all-oral combina-
tion regimen was approved, and trials have demonstrated SVR rates approaching 100% [5–9]. 
With their unprecedented efficacy and improved tolerability, they have revolutionized the 
approach to treatment of chronic hepatitis C.
2. Direct-acting antivirals
2.1. First-generation NS3/4A protease inhibitors
The HCV RNA genome encodes a single polyprotein consisting of 3000 amino acids, which 
is cleaved by host and viral-encoded proteases to yield the functional structural and non-
structural components of the virus [10]. The NS3/4A is composed of a serine protease (NS3) 
and cofactor (NS4A) and is involved in posttranslational processing or cleavage of the non-
structural components at the NS3/NS4A, NS4A/NS4B, NS4B/NS5A, and NS5A/NS5B sites. 
The NS3/4A protease is essential to the processing of the HCV polypeptide and is critical for 
replication of the virus [10].
In 2011, boceprevir and telaprevir were the first DAAs, and the first NS3/4A inhibitors to be 
approved for the treatment of chronic hepatitis C, genotype 1. The mechanism of action is to 
inhibit the NS3/4A protease by forming a reversible covalent bond with the NS3/4A active site 
[11]. Both boceprevir and telaprevir were found to have significant side effects, including ane-
mia and anemia plus rash, respectively [11]. In addition, their use was complicated by significant 
drug-drug interactions (both boceprevir and telaprevir are potent cytochrome p450 inhibitors), 
inconvenient dosing requiring multiple daily doses, and low barriers to resistance [11].
2.2. Second-generation protease inhibitors
A second generation of protease inhibitors was designed to contain macrocycles, or cyclic 
macromolecules, which resulted in improved antiviral potency [12]. Simeprevir was the first 
macrocyclic protease inhibitor to be approved for HCV treatment [13]. Simeprevir forms a 
noncovalent bond with the NS3/4A active site rather than the reversible covalent bond that 
boceprevir and telaprevir formed [14]. Paritaprevir is a protease inhibitor given in combina-
tion with three other medications (ombitasvir, paritaprevir, and dasabuvir), which comprise 
Viekira Pak, approved by the FDA in 2014 for HCV genotype 1. This was the second all-
oral, interferon-free, fixed-dose combination for treatment of chronic HCV genotype 1 to be 
approved in the US [15]. Grazoprevir is another second-generation protease inhibitor that was 
FDA approved in 2016 in combination with an NS5A inhibitor [16]. Asunaprevir is a potent, 
selective NS3 protease inhibitor with activity against HCV genotypes 1, 4, 5, and 6 in vitro 
and is given in combination with daclatasvir, discussed in the next section [17]. Benefits of 
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second-generation protease inhibitors include reduced dosing, improved side effect profiles, 
and fewer drug-drug interactions [18].
2.3. NS5A inhibitors
The NS5A phosphoprotein has no known enzymatic activity and its detailed function remains 
unclear [19]. NS5A inhibitors are thought to interact with NS5A and block formation of the 
“membranous web” that houses HCV RNA replication. They interfere with several functions 
of NS5A in the HCV life cycle, and disrupt the establishment of replication sites, which in turn 
prevents continued HVC RNA replication [19]. NS5A inhibitors include daclatasvir, ombi-
tasvir, ledipasvir, elbasvir, and velpatasvir. Daclatasvir can be given in combination with 
sofosbuvir +/− RBV for the treatment of HCV genotypes 1–4. Ombitasvir is approved for treat-
ment of genotype 1 in combination with paritaprevir, ritonavir, and dasabuvir. Ledipasvir is 
approved for genotypes 1, 3, and 4 in combination with sofosbuvir +/− RBV [20]. Velpatasvir 
in combination with sofosbuvir was approved in June 2016 by the FDA and became the first 
regimen approved for genotypes 1–6 [21].
2.4. Polymerase NS5B inhibitors
Polymerase inhibitors are another class of DAAs and are comprised of nucleoside analog and 
nonnucleoside analog inhibitors. Both types bind to the NS5B polymerase to terminate rep-
lication of the virus. The enzyme has a catalytic site for nucleoside binding and at least four 
other sites at which a nonnucleoside compound can bind and induce allosteric alterations in 
conformation [22].
Nucleoside analog inhibitors are incorporated into the HCV RNA chain and lead to direct 
chain termination. The advantage of this mechanism of action is that it is potentially active 
against all HCV genotypes, and the potential for viral resistance is low. This is because the 
NS5B active site has a low tolerance for amino acid substitutions. Any NS5B active site muta-
tion that would potentially confer resistance to a polymerase inhibitor would likely also impair 
the RNA polymerase activity. Sofosbuvir is an example of a nucleoside analog inhibitor for 
use in treatment of HCV. It is given orally once a day, has pan-genotypic antiviral activity, and 
has a high barrier to viral resistance with no virologic breakthrough reported thus far [23].
Nonnucleoside analog inhibitors bind to discrete sites outside of the polymerase active center 
and induce a conformational protein change. Dasabuvir is an example of a nonnucleoside 
inhibitor of the NS5B polymerase [24].
In comparison with the nucleoside analog inhibitors, nonnucleoside polymerase inhibitors 
are more genotype-specific and have a lower barrier to resistance. This class of drugs is used 
in combination with other classes that are more potent with higher barriers to resistance.
2.5. Role of ribavirin in the era of direct-acting antivirals
Ribavirin was a critical component of hepatitis C treatment in the era of interferon-based 
therapy; however, its role in DAA regimens was initially unclear. At this time, guidelines 
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do recommend the use of ribavirin in combination with DAAs, depending on genotype and 
presence or absence of cirrhosis. For example, there is evidence to support the use of ribavirin 
in specific situations, such as patients using sofosbuvir-based regimens who are either HCV 
genotype 1, treatment-experienced, and cirrhotic, or HCV genotype 3 with cirrhosis [25]. SVR 
rates tend to be lower among HCV genotype 3 patients with advanced liver disease (as low 
as 62% in patients with cirrhosis who were null responders to IFN-RBV therapy) [26]. In 
the ALLY-3+ study, ribavirin was investigated in combination with daclatasvir and sofosbu-
vir in patients who were HCV genotype 3, both treatment-naïve and treatment-experienced, 
and with advanced fibrosis or compensated cirrhosis. They achieved an overall SVR rate at 
12 weeks of 90% [27]. These results, in combination with other studies, support the addition 
of ribavirin to achieve higher rates of SVR, allow shortening of treatment, and decrease the 
cost of treatment.
3. Treatment strategies
The ultimate goal of antiviral therapy for patients with chronic hepatitis C is achieving 
SVR. Refer to Table 1 for additional terminology used to define treatment responses.
Monitoring viral levels during treatment with the new DAA regimens has minimal value, 
as the viral level is typically undetectable after 4 weeks of treatment. The more important 
assessment of virologic response is measuring the viral load at 12–24 weeks after therapy is 
completed or stopped.
When deciding on an appropriate DAA regimen, several factors must be taken into account, 
particularly HCV genotype, prior treatment history, stage of liver disease, presence of decom-
pensation in patients with known cirrhosis, renal function, and other medications the patient 
is taking that could interact with the DAAs.
3.1. Treatment-naïve patients
Refer to Table 2 for an overview of treatment regimens recommended based on American 
association for the study of liver diseases (AASLD) and infectious diseases society of America 
Nonresponse Detectable HCV RNA after 12 weeks of HCV therapy
Partial response >2 log decline in HCV RNA but detectable HCV RNA after 12 weeks of HCV 
therapy
Null response <2 log decline in HCV RNA after 12 weeks of HCV therapy
Viral breakthrough Detectable HCV RNA after previously undetectable
Relapse Undetectable HCV RNA on therapy with detectable HCV RNA after stopping 
therapy
Sustained virologic response Undetectable HCV RNA 12 or 24 weeks after stopping therapy
Table 1. Definitions of treatment response to HCV treatment.
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(IDSA) guidelines from April 2017. Compared to previous guidelines from July 2016, there is 
now a subcategory of patients who qualify for treatment of 8 weeks duration. Otherwise, the 
remainder of treatment regimens are all at least 12 weeks. This recommendation was based 
Genotype 
1a
Without cirrhosis • Daily elbasvir/grazoprevir*
• Daily ledipasvir/sofosbuvir**
• Daily paritaprevir/ritonavir/ombitasvir plus twice-daily dosed dasabuvir 
with weight-based ribavirin
• Daily simeprevir plus sofosbuvir
• Daily sofosbuvir/velpatasvir








Without cirrhosis • Daily elbasvir/grazoprevir
• Daily ledipasvir/sofosbuvir**
• Daily paritaprevir/ritonavir/ombitasvir plus twice-daily dosed dasabuvir
• Daily simeprevir plus sofosbuvir
• Daily sofosbuvir/velpatasvir





• Daily paritaprevir/ritonavir/ombitasvir plus twice-daily dosed dasabuvir
• Daily sofosbuvir/velpatasvir









• Daily daclatasvir plus sofosbuvir for 24 weeks with or without weight-
based ribavirin
















Dosing: elbasvir 50 mg, grazoprevir 100 mg, ledipasvir 90 mg, sofosbuvir 400 mg, paritaprevir 150 mg, ombitasvir 
25 mg, dasabuvir 250 mg, simeprevir 150 mg, ritonavir 100 mg, velpatasvir 100 mg.*In whom no baseline NS5A RAVs 
for elbasvir are detected.
**For patients who are nonblack, HIV-uninfected, and whose HCV RNA level is <6 million IU/mL, treatment duration 
is 8 weeks.
Table 2. Regimens for treatment-naïve patients (dosing for 12 weeks unless specified).
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on the ION-3 trial, which compared SVR rates in patients treated for 8 weeks versus 12 weeks 
and found no difference. However, relapse rates were higher in patients with certain charac-
teristics. Thus, the recommendation of 8 weeks of treatment is indicated in patients with HCV 
genotype 1a/1b without cirrhosis who are nonblack, human immunodeficiency virus (HIV)-
uninfected, and whose HCV RNA level is 6 million IU/mL.
3.2. FDA-approved regimens
While the direct-acting antivirals have been discussed up to this point as separate categories, it is clear 
based on the guidelines that most regimens include drugs from many categories. Pharmaceutical 
companies manufacture the drugs as combination pills, which makes dosing convenient.
Brand Name Components Year approved by FDA



















Table 3. Hepatitis C treatment regimens and their components.
GT1 GT2 GT3 GT4 GT5 GT6
Harvonia Sovaldi/RBV Sovaldi/Daklinza Harvoni Harvoni Harvoni
Zepatierf Peg-IFN/RBVd Sovaldi/RBVd PegIFN/Sovaldi/RBV
Viekira +/− RBVc Peg-IFN/RBVe Technivieb
Peg-IFN/Sovaldi/RBV Zepatier
Epclusag Epclusa Epclusa Epclusa Epclusa Epclusa
aTreatment experienced: 24-week course.
bContraindicated in cirrhotics.
cGenotype 1a: add ribavirin, 12-week course; genotype 1a cirrhotics, add ribavirin, 24-week course.
d24-week course.
e48-week course.
fGenotype 1a with polymorphism: add ribavirin, 16-week course.
gAdd ribavirin for Child-Pugh class B and C.
Table 4. FDA-approved regimens based on genotype (12-week course except where indicated).
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Refer to Table 3 for the brand names of hepatitis C treatment regimens and their components. 
Table 4 provides the approved regimens based on the genotype.
4. Special populations
4.1. Coinfection with HIV
Approximately 10–30% of patients with human immunodeficiency virus (HIV) also have 
HCV [28], with a global prevalence estimated at 2.5–5 million people [29]. With the improved 
lifespan of HIV patients attributable to effective antiretroviral therapy, the focus is now shift-
ing to treatment of concurrent infections that afflict HIV patients, with HCV-related liver 
complications being a leading non-HIV cause of death [30].
A meta-analysis study examined the survival benefit of achieving SVR, looking at a total of 
33,360 patients with HCV and HIV/HCV coinfection [31]. Achieving HCV SVR was associated 
with a 50% reduction in the risk of all-cause mortality compared with not achieving SVR in 
the general HCV population. This result was markedly higher for the coinfected subgroup 
(79%), highlighting the importance and potential impact HCV cure has on patients also co-
infected with HIV.
The ION-4 study studied outcomes for patients with HIV/HCV coinfection that were given 
DAAs while on antiretroviral therapy for HIV [32]. There were 335 patients enrolled in the 
study, most of which were genotype 1 (98%). In addition, 55% of the patients were treatment 
experienced. They were administered ledipasvir and sofosbuvir (Harvoni). After 12 weeks of 
therapy, 96% were HCV RNA negative, and SVR rates of >94% were observed. None of the 
patients discontinued treatment due to adverse events.
Another DAA regimen combining elbasvir, an NS5A inhibitor, with grazoprevir, a second-
generation NS3/4A protease inhibitor (Zepatier), was approved by the FDA for the treatment 
of chronic HCV genotypes 1 and 4, including those with HIV-1 coinfection. This indication 
was based on the C-EDGE CO-INFECTION study, which studied 218 patients with HIV/HCV 
coinfection who were treated with the elbasvir-grazoprevir combination [33]. Study results 
demonstrated an SVR rate of 96% at 12 weeks.
4.2. Coinfection with HBV
In the US, about 800,000–1.4 million people have chronic hepatitis B virus (HBV) infection. 
Around 2–10% of patients with chronic HCV are coinfected with HBV [34–36]. It has been 
shown that the presence of HBV coinfection with HCV accelerates the progression of liver 
damage, and is associated with a higher probability of liver cirrhosis and hepatic decompen-
sation, higher incidence of hepatocellular carcinoma, and death [36, 37].
A potentially serious complication of stable HBV infections is the phenomenon of reactivation 
in which viral replication and liver damage suddenly increase. HBV reactivation can occur 
in patients who are hepatitis B surface antigen (HBsAg) (+), patients who have HBV DNA (+) 
active infection, or in patients with inactive infections, i.e., who are HBsAg (−), HBV DNA (−), 
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but anti-HB virus core antibody (HBcAb) (+) and/or anti-HB virus surface antibody (HBsAb) 
(+) [38]. Reactivation can occur spontaneously, but more commonly occurs as a complication 
of medically induced changes in immune status. This has been clearly observed in patients 
with HBV infection who received antitumor necrosis factor (TNF) biologicals.
For this reason, the FDA has issued a black box warning concerning the risk of HBV reac-
tivation in patients receiving anti-TNF and anti-CD20 monoclonal antibodies [39]. HBV 
reactivation has also been reported in patients with HBV/HCV coinfections treated with the 
combination of daclatasvir and asunaprevir. [40]. Accordingly, the FDA has issued a Drug 
Safety Communication about the risk of HBV reactivation in patients with current or previous 
infection who are to be treated with direct-acting antiviral (DAA) agents for HCV. The FDA is 
considering a boxed warning for nine DAAs in addition to Harvoni including Sovaldi, Viekira 
Pak, Viekira Pak XR, Daklinza, Epclusa, Olysio, Technivie, and Zepatier.
It is important that health-care professionals screen and monitor for HBV in all patients before 
initiating treatment with DAAs [41]. Coinfected HBV patients should receive anti-HBV ther-
apy prior to and during anti-HCV treatment as prophylaxis against reactivation. Antiviral 
therapy started after HBV reactivation may not be effective to prevent hepatitis and/or hepa-
titis flares. The possible interaction of DAAs with some anti-HBV agents must also be consid-
ered [40, 42, 43].
4.3. Previously treated patients
There have been many studies that investigated retreatment strategies after lack of SVR with 
either an IFN-based regimen or an IFN-free regimen.
In the combination of simeprevir and sofosbuvir in HCV-infected patients (COSMOS) study 
(COSMOS) study trial, there were 80 HCV genotype 1 patients who were null responders to 
previous treatment with pegylated interferon and ribavirin. They were subsequently treated 
with simeprevir and sofosbuvir +/−ribavirin for 24 weeks, and achieved a mean SVR of 90%. 
In the ION-2 study, 440 HCV genotype 1 patients who were previously treated with an IFN-
based regimen were given sofosbuvir + ledipasvir +/− RBV for 12–24 weeks, and achieved a 
SVR rate of greater than 94%.
In the retreatment of patients with genotype 1a and 1b who previously failed peg-interferon 
and ribavirin therapy, current guidelines recommend the same 12-week regimens used as 
initial treatment for genotype 1a and 1b patient without cirrhosis [44].
There have been a few small studies examining treatment failure with IFN-free regimens, and 
results have been promising, demonstrating that retreatment can successfully achieve SVR, 
by either prolonging the duration of treatment to 24 weeks or by adding ribavirin [45]. The 
retreatment regimen should include sofosbuvir with 1–3 other DAAs with different mecha-
nisms of action.
4.4. Post-liver transplant patients
For patients with untreated recurrent hepatitis C after liver transplantation, disease pro-
gression is accelerated, with approximately 20% developing graft cirrhosis by 5 years 
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posttransplantation [46]. DAA regimens have significantly improved SVR rates in post-
transplant patients. The CORAL-I study looked at recurrent HCV genotype 1 infection in 
patients who had received liver transplants. These patients were treated with combina-
tion ombitasvir/paritaprevir/ritonavir plus dasabuvir with ribavirin for 24 weeks, and they 
achieved an SVR rate of 97% after 24 weeks of therapy [47].
5. Resistance to DAAs
NS5A inhibitors, NS3/4A protease inhibitors, and nonnucleoside polymerase inhibitors have 
low barriers to resistance. Prior to any antiviral treatment, resistance-associated variants 
(RAV) may preexist at varying frequencies and these variants may be selected rapidly during 
treatment with DAAs. However, with a few exceptions, HCV drug resistance testing is not 
recommended in naïve patients, because SVR rates were not affected by the presence of base-
line NS3/4A or NS5A RAVs [45]. Moreover, the majority of treatment failures with DAAs are 
usually related to relapse rather than on-treatment viral breakthrough [48].
Although resistance testing is not routinely recommended for all DAAs at this time, it is an 
important focus of research because it could guide regimen choices if patients at high risk for 
treatment failure were identified early. However, there are many conditions to be met prior to 
the widespread use of HCV resistance testing including a standardized assay, interpretation 
and reporting of the data [45].
At this time, these criteria have not been met. As discussed above, not all RAVs are clinically 
significant, and the level of resistance conferred by a preexisting RAV needs to be further 
delineated.
6. Barriers to treatment
With the recent success of DAA regimens and their exceptional SVR rates demonstrated in 
most recent trials, the prospect of eradicating HCV infection seems near. However, there still 
exist multiple barriers to treatment. The most obvious barrier is the high cost associated with 
treatment.
Drug pricing is impacted by many factors, including market competition, presence of 
generic versions, existing prices of effective treatment, and business negotiations. There 
is very little transparency in the process, particularly in the negotiations between phar-
maceutical companies and payers. However, the basis for negotiation starts with a list 
price set by the pharmaceutical company, called the Wholesale Acquisition Cost (WAC). 
Refer to Table 5 for the wholesale acquisition costs of the current HCV regimens on the 
market.
In the US, sofosbuvir was approved in 2013, and the WAC was set at $84,000 for a 12-week course 
of treatment [49]. The more recent development of market competition has created opportunity for 
greater discounts and rebates. When Viekira Pak (ombitasvir/paritaprevir/ritonavir + dasabuvir) 
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was approved, it was made available for $51,000–$66,000 [50]. Currently, 80% of the market is exclu-
sive to either Harvoni (Ledipasvir/Sofosbuvir) or Viekira Pak, and the average negotiated discount 
is 46% off of the WAC [51].
Until DAAs become widely affordable, there will be restrictions, and priority will be given 
to those who have failed previous IFN-based therapies with evidence of disease progression, 
patients ineligible for IFN-based therapy with progressive disease, patients with established 
cirrhosis, patients on the liver transplant waiting list, and those who have had a liver transplant.
7. Conclusions
This is a pivotal time in which there have been major advances in the treatment of hepatitis 
C. Patients have the option of an all-oral regimen with high tolerability and convenient dosing. 
With SVR nearing 100%, the prospect of limiting HCV treatment failures appears to be promis-
ing. It is important to recognize the potential of these current regimens and minimize the emer-
gence of resistant HCV. Avoidance of development of drug resistant virus is best achieved by 
using HCV regimens that incorporate agents with different mechanisms of action. Some strides 
have been made in accessibility and affordability, but there remains a large proportion of HCV-
infected patients for which treatment needs to be made available prior to disease progression. 
Finally, there needs to be continued screening and education to reduce the prevalence.
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Direct-acting antiviral Pharmaceutical company WAC for 12-week 
course
Sofosbuvir (Sovaldi) Gilead sciences $84,000
Ledipasvir/Sofosbuvir (Harvoni) Gilead sciences $94,500
Ombitasvir/paritaprevir/ritonavir + Dasabuvir (Viekira Pak) AbbVie $83,319
Daclatasvir (Daklinza) + Sofosbuvir (Sovaldi) Bristol-Myers Squibb and 
Gilead
$147,000
Grazoprevir/Elbasvir (Zepatier) Merck $54,600
Sofosbuvir/Velpatasvir (Epclusa) Gilead sciences $74,760
Table 5. Wholesale Acquisition Cost of direct-acting antivirals.
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